StockData

InspireMD vs Beyond Air

NSPR and XAIR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NSPR and XAIR compare

InspireMD is the larger company, worth 14 times as much as Beyond Air ($27.9M against $1.9M).

Beyond Air grew revenue faster over the last twelve months (60.7% versus 53.4% for InspireMD).

Beyond Air keeps more of each dollar of sales as profit, with a net margin of −436% compared with −484% at InspireMD.

InspireMD scores higher on the StockData Score (10 against 6 for Beyond Air), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNSPRXAIR
Size and price
Market cap$27.9M$1.9M
Share price$0.600$2.02
Change, 1 year−67.9%−92.9%
Change, 5 years−83.5%−100.0%
Beta (5Y)−0.76−0.21
Employees12754
StockData Score
Total score10 (better)6
Valuation score33
Growth score22
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S2.6×0.3× (better)
P/B0.9× (better)1.0×
FCF yield−152% (better)−1013%
Fair value$1.40$12.82
Margin of safety57.0%84.2% (better)
Growth
Revenue growth (TTM)53.4%60.7% (better)
Revenue growth, 5Y average29.3%54.5% (better)
Profitability
Gross margin18.1% (better)4.2%
Operating margin−494%−365% (better)
Net margin−484%−436% (better)
FCF margin−392%−255% (better)
Return on equity−203% (better)−562%
Return on invested capital−4320%–
Financial health
Debt / equity0.00–
Interest coverage–−6.3×
Current ratio3.80 (better)3.31
Altman Z-score−12.08 (better)−15.90
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.6%7.2%
Held by insiders31.6%–
Insider net buying, 12 months$369K (better)$287K
Short interest, % of float0.79%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.